Skip to main content
padlock icon - secure page this page is secure

Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?

Buy Article:

$62.00 + tax (Refund Policy)

This study was undertaken to determine the association between extrarenal tumor spread and size in a series of well-sampled clear cell renal cell carcinoma (ccRCC). In a series of 917 cases of ccRCC, 178 were >7 cm in maximum extent. Assessment of tumors >7 cm in size showed 72 (40.4%) to have renal sinus infiltration, the tumor infiltrating perirenal fat in 7 (3.9%) cases, and both in 96 (53.9%) cases. In the remaining 3 (1.7%) cases, no extrarenal extension of the tumor was seen. These 3 cases with organ-confined ccRCC were all cystic tumors. Two showed extensive infarction with associated hemorrhage and the presence of a thick investing pseudocapsule, while the third was a cystic ccRCC arising in the upper pole of the kidney. For the ccRCCs in the series that were ≤7 cm in maximum extent, division of cases according to tumor size and pT staging category showed an increase in the proportion of tumors showing extrarenal spread with increasing size, ranging from 0% for tumors <1 cm in diameter to 84.7% for tumors >6 to 7 cm. The study has shown that for ccRCC, the extrarenal spread of tumor is strongly associated with the size of the primary tumor. The study has also shown that renal sinus invasion and/or perirenal fat infiltration by tumor is commonplace in tumors >7 cm in maximum extent and that tumors of this dimension are rarely organ-confined. These findings provide evidence that the defining features of pT1, pT2, and pT3a staging categories for ccRCC require revision.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: clear cell renal cell carcinoma; international society of urological pathology; prognosis; renal sinus; stage

Document Type: Research Article

Affiliations: 1: Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand, Aquesta Specialized Uropathology 2: Aquesta Specialized Uropathology, Rennes University Hospital, University of Rennes, Rennes, France 3: Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden 4: Wesley Hospital, University of Queensland School of Medicine, Brisbane, Qld, Australia 5: Department of Pathology, Cardiff and Vale University Health Board, Cardiff, UK 6: Aquesta Specialized Uropathology, University of Queensland School of Medicine, Brisbane, Qld, Australia

Publication date: September 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more